An inconvenient truth

Blood

Volumn 115, Issue 14, 2010, Pages 2727-2728

  Spivak, Jerry L ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYUREA; PEGINTERFERON;

CHROMOSOME 16Q; CHROMOSOME 19P; CHROMOSOME 21Q; GENE MUTATION; GENETIC ASSOCIATION; HOMOZYGOSITY; LEUKEMIA; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; NOTE; OVERALL SURVIVAL; PHENOTYPE; POLYCYTHEMIA VERA; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTOSIS;

EID: 77950990890     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-01-261412     Document Type: Note

References (10)

1. Thoennissen NH, Krug UO, Lee DH, et al. Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms. Blood. 2010; 115(14):2882-2890.
2. Beer PA, Delhommeau F, Lecouedic JP, et al. Two routes to leukemic transformation following a JAK2 mutation-positive myeloproliferative neoplasm. Blood. 2010; 115(14):2891-2900.
3. Berk PD, Goldberg JD, Silverstein MN, et al. Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy.NEngl J Med. 1981;304(8): 441-447. (Pubitemid 11178999)
4. Najean Y, Rain J. Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. Blood. 1997;90(9):3370-3377. (Pubitemid 27473405)
5. Zhao R, Follows GA, Beer PA, et al. Inhibition of the Bcl-xL deamidation pathway in myeloproliferative disorders. N Engl J Med. 2008;359(26):2778-2789.
6. Plo I, Nakatake M, Malivert L, et al. JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders. Blood. 2008;112(4):1402-1412.
7. Dawson MA, Bannister AJ, Gottgens B, et al. JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin. Nature. 2009;461(7265):819-822.
8. Harrison CN, Campbell PJ, Buck G, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. NEngl J Med. 2005;353(1):33-45. (Pubitemid 41007805)
9. Kiladjian JJ, Cassinat B, Chevret S, et al. Pegylated interferon-alfa-2a induces complete hematological and molecular responses with low toxicity in polycythemia vera. Blood. 2008;112(8):3065-3072.
10. Brodsky RA, Jones RJ. Riddle: what do aplastic anemia, acute promyelocytic leukemia, and chronic myeloid leukemia have in common? Leukemia. 2004;18(10):1740-1742.